Pyrosequencing/Mayo Deal Could Yield Thyroid Test ASR In Mid-2002
This article was originally published in The Gray Sheet
Executive Summary
Pyrosequencing could make an analyte specific reagent (ASR) submission with FDA as early as mid-2002 for a test to detect an inherited form of thyroid cancer, under development with the Mayo Clinic